Novavax Inc. (NVAX) Plunges 5.81% on December 17

Novavax Inc. (NVAX) Plunges 5.81% on December 17

Novavax Inc. (NVAX) had a rough trading day for Monday December 17 as shares tumbled 5.81%, or a loss of $-0.14 per share, to close at $2.27. After opening the day at $2.40, shares of Novavax Inc. traded as high as $2.41 and as low as $2.25. Volume was 12.26 million shares over 25,893 trades, against an average daily volume of n/a shares and a total float of 382.85 million.

As a result of the decline, Novavax Inc. now has a market cap of $869.07 million. In the last year, shares of Novavax Inc. have traded between a range of $2.75 and $1.05, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Novavax is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Novavax Inc. is based out of Gaithersburg, MD and has some 362 employees. Its CEO is Stanley Charles Erck.

error: Content is protected !!